- Home
- Protocols and Guidelines
- Upcoming CAP Guidelines
- Evaluation of MRD Testing in ALL
Background
The standard-of-care for monitoring treatment response in acute lymphoblastic leukemia (ALL) is minimal/measurable residual disease (MRD) testing. Several testing methodologies, including immunophenotypic (flow cytometric) and molecular (polymerase chain reaction and next-generation sequencing) assays, are currently utilized. Moreover, optimal treatment time points, sample types and quality, assay protocols, and interpretative strategies are not established. The goal of this guideline is to establish evidence-based standards and expert recommendations in the application, interpretation, and actionability of MRD for ALL (B-ALL and T-ALL, pediatric and adult).
Scope
The primary goal of this guideline is to address clinical evaluation of MRD in ALL. The evidence-based recommendations will focus on optimal MRD testing methods.
Guideline information
- Guideline status: Determine Scope & Form Panel
Expert Panel Members
Genevieve Crane, MD, PhD, FCAP, Co-chair
Alexandra Kovach, MD, FCAP, Co-chair
Daniel Boyer, MD, PhD, FCAP
Sindhu Cherian, MD, FCAP
Yi Ding, MD, FCAP
Mark Ewalt, MD, FCAP
Benjamin Hedley, PhD
Yen-Chun Liu, MD, PhD, FCAP
Lori Muffly, MD
Rachel Rau, MD
Julie Rosser, DO, FCAP
Julie Donovan, MLS(ASCP)
Lindsy Frazer-Green, PhD
Marisol Hernandez, MLS, MA
Tanja Kalicanin, MLS (ASCP) CM
Learn More
Review additional upcoming CAP evidence-based guidelines by the Center.